| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_496d53dec06c8978ccfe31d98e2759a7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fe38ea77c0736f116612b07c710ea4c9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_16fbfff10c3d68863163e3e87b7c3986
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d4260a256b5f28ea7d92b4c1f5b921d0 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-162
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-01 |
| filingDate |
2004-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_861a50fcc34790a5391c9ba0d7728fb8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_25b12182eef1fd68e839c887d09e3f1c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_83bc31cc9048f3fa98b77498aa955c88 |
| publicationDate |
2004-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2004075911-A1 |
| titleOfInvention |
Chemokine binding protein and use thereof |
| abstract |
Use of a composition comprising 35K is provided for the manufacture of a medicament for the treatment of atherosclerosis. We also provide, an adenoviral vector comprising a polynucleotide in expressible form encoding 35K for use in the treatment of an inflammatory disorder; in combination, an adenoviral vector encoding a therapeutic gene product and a composition comprising 35K for the treatment of the disorder treatable by expression of the therapeutic gene product; and in combination, a composition comprising 35K and an adenoviral vector expressing a therapeutic gene product for use in enhancing expression of the therapeutic gene product. |
| priorityDate |
2003-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |